Loading…
Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension
The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension. A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-o...
Saved in:
Published in: | Journal of pharmacological and toxicological methods 2008-05, Vol.57 (3), p.212-219 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3 |
container_end_page | 219 |
container_issue | 3 |
container_start_page | 212 |
container_title | Journal of pharmacological and toxicological methods |
container_volume | 57 |
creator | Bertera, Facundo M. Mayer, Marcos A. Opezzo, Javier A.W. Taira, Carlos A. Höcht, Christian |
description | The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension.
A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg
−
1
). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified
E
max model.
No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and
E
max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified
E
max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response.
Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical
E
max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified
E
max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified
E
max pharmacodynamic model is the most suitable for verapamil PK–PD modeling. |
doi_str_mv | 10.1016/j.vascn.2008.03.002 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71632824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1056871908000233</els_id><sourcerecordid>19609043</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</originalsourceid><addsrcrecordid>eNqFkU1uFDEQha0IRH7ICSIhr9h1U_7pbnuRBRpIQEQiC5Cyszx2NfGo227smZFmxx24ISdJDzNSdrCqUul7r0r1CLliUDNg7btVvbXFxZoDqBpEDcBPyBlTnaikUg8v5h6atlId06fkvJQVAAjN5CtyypSUXAs4I-MijZPNoaRIU0996HvMGNd0erR5tC75XbRjcHRMHodC-5Tp_Zc_v37ffziMQvyxF24x22kGBxoinQ3S_rbNYDN93E2Y1xhLSPE1ednboeDlsV6Q7zcfvy0-VXdfbz8v3t9VTkjFK2ZZYztUkotu6WXTyQYFiha8btzSKceFc0tp2w59x2VrNUPthRZcKyetFRfk7cF3yunnBsvajKE4HAYbMW2K6VgruOLyvyDTLWiQYgbFAXQ5lZKxN1MOo807w8Ds4zAr8zcOs4_DgDBzHLPqzdF-sxzRP2uO_5-B6wMw_xa3AbMpLmB06ENGtzY-hX8ueAKWip8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19609043</pqid></control><display><type>article</type><title>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</title><source>ScienceDirect Journals</source><creator>Bertera, Facundo M. ; Mayer, Marcos A. ; Opezzo, Javier A.W. ; Taira, Carlos A. ; Höcht, Christian</creator><creatorcontrib>Bertera, Facundo M. ; Mayer, Marcos A. ; Opezzo, Javier A.W. ; Taira, Carlos A. ; Höcht, Christian</creatorcontrib><description>The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension.
A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg
−
1
). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified
E
max model.
No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and
E
max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified
E
max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response.
Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical
E
max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified
E
max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified
E
max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.</description><identifier>ISSN: 1056-8719</identifier><identifier>EISSN: 1873-488X</identifier><identifier>DOI: 10.1016/j.vascn.2008.03.002</identifier><identifier>PMID: 18442930</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Aorta - surgery ; Aortic coarctation ; Aortic Coarctation - complications ; Aortic Coarctation - surgery ; Blood Pressure - drug effects ; Calcium Channel Blockers - pharmacokinetics ; Chronotropic effect ; Dose-Response Relationship, Drug ; Heart Rate - drug effects ; Hypertension, Renovascular - etiology ; Hypertension, Renovascular - metabolism ; Hypertension, Renovascular - physiopathology ; Hypotensive effect ; Injections, Intravenous ; Male ; Microdialysis ; Models, Biological ; Pharmacokinetic–pharmacodynamic modeling ; Plasma pharmacokinetics ; Rats ; Rats, Wistar ; Reproducibility of Results ; Verapamil ; Verapamil - pharmacokinetics</subject><ispartof>Journal of pharmacological and toxicological methods, 2008-05, Vol.57 (3), p.212-219</ispartof><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</citedby><cites>FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18442930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bertera, Facundo M.</creatorcontrib><creatorcontrib>Mayer, Marcos A.</creatorcontrib><creatorcontrib>Opezzo, Javier A.W.</creatorcontrib><creatorcontrib>Taira, Carlos A.</creatorcontrib><creatorcontrib>Höcht, Christian</creatorcontrib><title>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</title><title>Journal of pharmacological and toxicological methods</title><addtitle>J Pharmacol Toxicol Methods</addtitle><description>The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension.
A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg
−
1
). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified
E
max model.
No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and
E
max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified
E
max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response.
Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical
E
max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified
E
max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified
E
max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.</description><subject>Animals</subject><subject>Aorta - surgery</subject><subject>Aortic coarctation</subject><subject>Aortic Coarctation - complications</subject><subject>Aortic Coarctation - surgery</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - pharmacokinetics</subject><subject>Chronotropic effect</subject><subject>Dose-Response Relationship, Drug</subject><subject>Heart Rate - drug effects</subject><subject>Hypertension, Renovascular - etiology</subject><subject>Hypertension, Renovascular - metabolism</subject><subject>Hypertension, Renovascular - physiopathology</subject><subject>Hypotensive effect</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Microdialysis</subject><subject>Models, Biological</subject><subject>Pharmacokinetic–pharmacodynamic modeling</subject><subject>Plasma pharmacokinetics</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reproducibility of Results</subject><subject>Verapamil</subject><subject>Verapamil - pharmacokinetics</subject><issn>1056-8719</issn><issn>1873-488X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqFkU1uFDEQha0IRH7ICSIhr9h1U_7pbnuRBRpIQEQiC5Cyszx2NfGo227smZFmxx24ISdJDzNSdrCqUul7r0r1CLliUDNg7btVvbXFxZoDqBpEDcBPyBlTnaikUg8v5h6atlId06fkvJQVAAjN5CtyypSUXAs4I-MijZPNoaRIU0996HvMGNd0erR5tC75XbRjcHRMHodC-5Tp_Zc_v37ffziMQvyxF24x22kGBxoinQ3S_rbNYDN93E2Y1xhLSPE1ednboeDlsV6Q7zcfvy0-VXdfbz8v3t9VTkjFK2ZZYztUkotu6WXTyQYFiha8btzSKceFc0tp2w59x2VrNUPthRZcKyetFRfk7cF3yunnBsvajKE4HAYbMW2K6VgruOLyvyDTLWiQYgbFAXQ5lZKxN1MOo807w8Ds4zAr8zcOs4_DgDBzHLPqzdF-sxzRP2uO_5-B6wMw_xa3AbMpLmB06ENGtzY-hX8ueAKWip8w</recordid><startdate>200805</startdate><enddate>200805</enddate><creator>Bertera, Facundo M.</creator><creator>Mayer, Marcos A.</creator><creator>Opezzo, Javier A.W.</creator><creator>Taira, Carlos A.</creator><creator>Höcht, Christian</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200805</creationdate><title>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</title><author>Bertera, Facundo M. ; Mayer, Marcos A. ; Opezzo, Javier A.W. ; Taira, Carlos A. ; Höcht, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Animals</topic><topic>Aorta - surgery</topic><topic>Aortic coarctation</topic><topic>Aortic Coarctation - complications</topic><topic>Aortic Coarctation - surgery</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - pharmacokinetics</topic><topic>Chronotropic effect</topic><topic>Dose-Response Relationship, Drug</topic><topic>Heart Rate - drug effects</topic><topic>Hypertension, Renovascular - etiology</topic><topic>Hypertension, Renovascular - metabolism</topic><topic>Hypertension, Renovascular - physiopathology</topic><topic>Hypotensive effect</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Microdialysis</topic><topic>Models, Biological</topic><topic>Pharmacokinetic–pharmacodynamic modeling</topic><topic>Plasma pharmacokinetics</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reproducibility of Results</topic><topic>Verapamil</topic><topic>Verapamil - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bertera, Facundo M.</creatorcontrib><creatorcontrib>Mayer, Marcos A.</creatorcontrib><creatorcontrib>Opezzo, Javier A.W.</creatorcontrib><creatorcontrib>Taira, Carlos A.</creatorcontrib><creatorcontrib>Höcht, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmacological and toxicological methods</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bertera, Facundo M.</au><au>Mayer, Marcos A.</au><au>Opezzo, Javier A.W.</au><au>Taira, Carlos A.</au><au>Höcht, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension</atitle><jtitle>Journal of pharmacological and toxicological methods</jtitle><addtitle>J Pharmacol Toxicol Methods</addtitle><date>2008-05</date><risdate>2008</risdate><volume>57</volume><issue>3</issue><spage>212</spage><epage>219</epage><pages>212-219</pages><issn>1056-8719</issn><eissn>1873-488X</eissn><abstract>The aim of this work was to compare the suitability of different pharmacodynamic models for PK–PD modeling of verapamil cardiovascular effects in aortic coarctated rats (ACo), a model of renovascular hypertension.
A “shunt” microdialysis probe was inserted in a carotid artery of anaesthetized sham-operated (SO) and ACo rats for determination of verapamil plasma concentrations and their effects on blood pressure and heart rate after intravenous application (1 and 3 mg kg
−
1
). Correlation between verapamil plasma levels and their cardiovascular effects was established by fitting data to a linear, and a conventional and modified
E
max model.
No differences in verapamil volume of distribution were observed between experimental groups. Whilst clearance increased with dose in SO rats, no differences were found in verapamil clearance in ACo comparing both dose levels. A good correlation between verapamil plasma unbound concentrations and their hypotensive and chronotropic effects was found in both experimental groups using the tested PK–PD models. Although all pharmacodynamic models allowed a precise estimation of verapamil PK–PD parameters, linear and
E
max model did not permit an accurate PK–PD parameter estimation for the hypotensive and chronotropic effect, respectively. Conversely, the modified
E
max model allows both a precise and accurate estimation of PK–PD parameters for verapamil effects. Although, absolute verapamil blood pressure lowering effect was greater in ACo rats compared with SO rats, no differences were found in verapamil PK–PD parameters estimated for the hypotensive response.
Side-by-side comparison of the tested pharmacodynamic models showed that accuracy of PK–PD parameters estimation by using the linear and classical
E
max model depends on the magnitude of concentration–effect curve covered in the study. Conversely, the modified
E
max model allowed both a precise and accurate estimation of PK–PD parameters, suggesting that the modified
E
max pharmacodynamic model is the most suitable for verapamil PK–PD modeling.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18442930</pmid><doi>10.1016/j.vascn.2008.03.002</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1056-8719 |
ispartof | Journal of pharmacological and toxicological methods, 2008-05, Vol.57 (3), p.212-219 |
issn | 1056-8719 1873-488X |
language | eng |
recordid | cdi_proquest_miscellaneous_71632824 |
source | ScienceDirect Journals |
subjects | Animals Aorta - surgery Aortic coarctation Aortic Coarctation - complications Aortic Coarctation - surgery Blood Pressure - drug effects Calcium Channel Blockers - pharmacokinetics Chronotropic effect Dose-Response Relationship, Drug Heart Rate - drug effects Hypertension, Renovascular - etiology Hypertension, Renovascular - metabolism Hypertension, Renovascular - physiopathology Hypotensive effect Injections, Intravenous Male Microdialysis Models, Biological Pharmacokinetic–pharmacodynamic modeling Plasma pharmacokinetics Rats Rats, Wistar Reproducibility of Results Verapamil Verapamil - pharmacokinetics |
title | Comparison of different pharmacodynamic models for PK–PD modeling of verapamil in renovascular hypertension |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A38%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20different%20pharmacodynamic%20models%20for%20PK%E2%80%93PD%20modeling%20of%20verapamil%20in%20renovascular%20hypertension&rft.jtitle=Journal%20of%20pharmacological%20and%20toxicological%20methods&rft.au=Bertera,%20Facundo%20M.&rft.date=2008-05&rft.volume=57&rft.issue=3&rft.spage=212&rft.epage=219&rft.pages=212-219&rft.issn=1056-8719&rft.eissn=1873-488X&rft_id=info:doi/10.1016/j.vascn.2008.03.002&rft_dat=%3Cproquest_cross%3E19609043%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3482-1a15a7e84237bd45745e3e360d95cbc8c23ccb4a67ed7246a91e9d393298c4aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19609043&rft_id=info:pmid/18442930&rfr_iscdi=true |